Compare CADL & UXIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CADL | UXIN |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 578.8M | 495.0M |
| IPO Year | 2021 | 2018 |
| Metric | CADL | UXIN |
|---|---|---|
| Price | $8.83 | $2.26 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $19.00 | N/A |
| AVG Volume (30 Days) | ★ 2.2M | 100.4K |
| Earning Date | 05-14-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $245.77 |
| Revenue Next Year | N/A | $44.72 |
| P/E Ratio | ★ N/A | $4.05 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $2.01 |
| 52 Week High | $9.27 | $5.32 |
| Indicator | CADL | UXIN |
|---|---|---|
| Relative Strength Index (RSI) | 68.29 | 37.13 |
| Support Level | $4.80 | $2.01 |
| Resistance Level | $9.27 | $3.18 |
| Average True Range (ATR) | 0.60 | 0.15 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 75.28 | 38.24 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Uxin Ltd is an investment holding company. Along with its subsidiaries, the firm operates a car retailer, pioneering industry transformation with production, new retail experiences, and digital empowerment in China. With its inventory-owning model, it provides customers a comprehensive transaction solution that encompasses the entire value chain, ranging from used-car acquisition, inspection, and reconditioning, warehousing, as well as pre-sales and after-sales services. The group offers high-quality and value-for-money used cars as well as superior full suites of services to customers through a reliable, one-stop, and hassle-free transaction experience. It derives revenues from retail vehicle sales, wholesale vehicle sales, and other businesses. The Group generates its revenues in China.